Navigation Links
Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStent™ Drug-Eluting Coronary Stent (DES)
Date:2/17/2011

ardiac events and revascularization rates, the extent of stent coverage and re-endothelialization, via optical coherence tomography (OCT), and endothelial function (vasomotor response) will be evaluated in a subgroup of patients at nine months.  More information on the DESSOLVE II trial can be found at ClinicalTrials.gov.

"Drug-eluting stents have significantly improved and expanded our ability to treat coronary atherosclerotic lesions compared to bare-metal stents," said William Wijns, M.D., Cardiovascular Center, Aalst, Belgium, and principal investigator of the study. "However, cardiologists are still looking for options to improve safety and outcomes. The MiStent DES may address some of these issues directly.  Based on recent GLP animal data, the polymer and drug are gone from the stent within 45 to 60 days.  This may reduce the risk of late-stent thrombosis related to long-term exposure to DES non-erodible polymers.  Given the relatively short residence time of polymer on the stent, MiStent DES may allow for a shorter duration of dual anti-platelet therapy and be a safer choice for non-compliant patients. These performance-enhancing properties are what interventional cardiologists are looking for in a new drug-eluting stent."

Arthur J. Benvenuto, Chairman and Chief Executive Officer of Micell, added, "The MiStent DES has the potential to uniquely combine safety and efficacy with excellent deliverability.  If these important patient benefits are confirmed in clinical trials, the MiStent DES performance and safety would be highly differentiated from both current DES offerings and from DES candidates known to be in development."

About the MiStent DESThe MiStent DES is a drug-eluting stent designed to optimize healing. The Company's rapid-absorbing drug/polymer formulation is inten
'/>"/>

SOURCE Micell Technologies Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
3. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
4. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
5. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
8. Senesco Technologies Initiates Preclinical Studies for Cancer Target
9. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
10. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
11. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... today announced it has established a relief fund ... that has gripped much of the nation. AARP and its ... support these emergency relief efforts AARP and AARP Foundation will ... to $500,000 in aid. The matching program will be administered ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
(Date:1/15/2014)... , January 15, 2014 BreedIT ... the exclusive worldwide distributor of highly sophisticated agro-breeding solutions ... January 7, 2014, the Company,s board of directors appointed ... as its new member of the board. ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... 2011 The New Jersey Patient Care and Access Coalition ... encourages men and their families to speak out to preserve ... Force (USPSTF) recommended healthy men should no longer receive prostate-specific ... This decision was made by a panel ...
... 2011 Masimo (NASDAQ: ... Japanese Ministry of Health Labor & Welfare (MHLW) ... rainbow® Acoustic Monitoring technology—providing noninvasive and continuous acoustic ... and enhance patient compliance.  Available for the first ...
Cached Medicine Technology:NJ Docs Say Cancer Detection Tool Saves Lives 2Masimo rainbow Acoustic Monitoring Technology Cleared for Market in Japan 2Masimo rainbow Acoustic Monitoring Technology Cleared for Market in Japan 3Masimo rainbow Acoustic Monitoring Technology Cleared for Market in Japan 4Masimo rainbow Acoustic Monitoring Technology Cleared for Market in Japan 5Masimo rainbow Acoustic Monitoring Technology Cleared for Market in Japan 6
(Date:4/18/2014)... (Seattle, WA April 18, 2014) Benaroya Research ... to research how blocking a particular molecule in metastatic ... and the number of lung metastases. BRI scientists have ... protein can shrink tumors by 60 - 80 percent ... to the lung. The $1.8 million five-year grant comes ...
(Date:4/18/2014)... discovery by Northwestern Medicine scientists could lead to potential ... in people with scleroderma. , Fibrosis, or scarring, ... of the skin and lungs can lead to serious ... concept for new therapeutic options centers on findings made ... who identified the role that a specific protein plays ...
(Date:4/17/2014)... new pain relief targets that could be used ... at King,s College London made the discovery when ... periphery of the body. , Dr Marzia Malcangio ... underlying pain generation and our findings could help ... , One potential side effect of some chemotherapy ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2
... Herley Industries, Inc. (Nasdaq: HRLY ) announced today ... contracts valued at approximately $4 million to provide various complex ... follow-on awards for an existing customer and program. The hardware ... , , Herley Industries, Inc. acquired Eyal Microwave Industries, ...
... before prescribing, researcher says , THURSDAY, June 4 (HealthDay ... the elderly, Swedish researchers say. , In their study, ... of suicides in older people. "Sedative treatment was associated ... the crude analysis and remained an independent risk factor ...
... London, New Delhi, Singapore and Washington DC (4 June, ... journal Palliative Medicine is to become the ... Formed in 1986, The Association for Palliative Medicine of ... doctors who work in hospices and specialist palliative care ...
... French . , Montreal, June 4th, 2009 ... a disease that results in severe breathing difficulty. According to ... worldwide. However the mechanisms responsible for some smokers developing COPD ... Dr.Manuel Cosio from the McGill University Health Centre, ...
... Frontiers in Labor and Employment Relations: Ensuring Good Jobs, ... , , , WASHINGTON, June 4 ... Employment Relations Association on June 11-12, 2009, features the ... on the auto crisis, top national experts on health ...
... The Usual With A Gift That Does Wonders For His ... , PACIFIC PALISADES, Calif., June 4 Forget ties ... he secretly desires but may not buy for himself: An ... hero. Dermagenics Physician-Formulated Anti-Wrinkle Moisturizer is an ...
Cached Medicine News:Health News:Herley's Israeli Subsidiary, GMI Eyal, is Selected to Provide Complex Microwave Switch Assemblies for a U.S. Customer 2Health News:Sedatives Increase Suicide Risk Among Elderly 2Health News:Investigation finds that cigarette smoking does not affect everyone in same way 2Health News:LERA National Policy Forum Set for June 11-12 in Washington, D.C. 2Health News:LERA National Policy Forum Set for June 11-12 in Washington, D.C. 3Health News:SHOW DAD YOU LOVE HIS FACE 2
... 1300 C is ideal for evaluating a wide ... parts of the body. Often referred to at ... magnetocardiography, gastrointestinal tract, fetal, spinal cord and peripheral ... C, with its 67 detector coils, covers a ...
... table configurations designed for a wide range ... capture 17 X 17 X-ray images from ... system includes a Bucky table, upright tilting ... suspended multi-positioning unit. Versatile and economical, the ...
... synthetic bone filler tailored for slow ... and Hydroxyapatite (HAP), its composition mimics ... the chemistry and microstructure of Bi-Ostetic ... provides optimal osteo-conduction. The spongy Bi-Ostetic ...
The TB Lead is a high quality bipolar intracardiac lead for cost effective temporary pacing and electrophysiology studies. The TB lead is available in sizes ranging from 4F to 6F and comes in either ...
Medicine Products: